The Cambridge biotech turned messenger RNA from a lab curiosity into a platform for printing medicines from genetic code - vaccines, cancer shots, and rare-disease drugs that share one factory and swap out the instructions.
For most of its history, Moderna sold nothing. It had no pills, no shots, no approved product of any kind - just a conviction that a fragile molecule called messenger RNA could be turned into a general-purpose way of making medicine. That conviction lasted roughly a decade, through skepticism, cash burn and repeated fundraising, before the world suddenly needed exactly what the company had spent ten years learning to build.
When a novel coronavirus surfaced in early 2020, Moderna's scientists did not go looking for a molecule in a haystack. They downloaded a genetic sequence and, within about two days, had designed a vaccine candidate. The first doses reached human trials in roughly 63 days. The speed startled the public, but inside the company it was the whole point: if mRNA is the instruction and the body is the factory, then designing a new medicine looks less like chemistry and more like writing code.
The idea in one sentence
Moderna's central bet is that mRNA is a platform, not a product. Messenger RNA is the molecule that carries instructions from your genes to the cellular machinery that builds proteins. Feed the body the right mRNA, the thinking goes, and you can prompt it to make almost any protein you want - a viral spike to train immunity, a missing enzyme in a rare disease, or a flag that helps the immune system recognize a tumor.
The commercial consequence is unusual for a drug company. Traditional pharma discovers one molecule, patents it, and defends it for two decades. Moderna reuses a single manufacturing process and swaps the genetic instructions to make the next candidate. The code changes; the machine mostly does not.
Same core, different instructions. Change the genetic code, keep the infrastructure - the reason a new candidate can be designed in days rather than years.
What it sells today
Moderna currently has three commercial products, all vaccines. Spikevax is the original mRNA COVID-19 vaccine, first authorized in the United States in December 2020; in July 2025 the FDA approved it for children six months through 11 years at increased risk. mNEXSPIKE, a next-generation, lower-dose COVID vaccine, was approved in May 2025 for adults 65 and older and for people 12 to 64 with at least one risk factor. mRESVIA, the company's vaccine against respiratory syncytial virus, had its indication expanded in June 2025 to include at-risk adults aged 18 to 59, adding to the existing group of adults 60 and over.
Behind the three products sits a pipeline built on the same platform. A seasonal influenza vaccine, mRNA-1010, reported Phase 3 efficacy and safety data in 2025, with the company targeting regulatory submissions across the United States, Canada, Australia and Europe. Further out are investigational programs in latent and other infectious diseases and in rare genetic conditions - each one, in principle, a new set of instructions rather than a new factory.
"The design is essentially a digital file. That is what makes a decade of platform-building pay off in a matter of days."
The most personal medicine it makes
The clearest glimpse of where the platform is headed is oncology. Together with Merck, Moderna is developing intismeran autogene (also known as mRNA-4157 or V940), an individualized neoantigen therapy. It is, quite literally, a cancer vaccine manufactured for a single person: a patient's tumor is sequenced, the specific mutations are identified, and a bespoke set of mRNA instructions is printed to train that patient's immune system to recognize and attack those mutations.
In high-risk melanoma, tested alongside Merck's Keytruda after surgery, five-year follow-up data showed the combination reduced the risk of recurrence or death by 49% compared with Keytruda alone - a figure that held steady from the three-year mark to the five-year mark. The program is being studied across additional tumor types, including lung, bladder and kidney cancers.
High-risk resected melanoma, recurrence-or-death risk versus Keytruda alone. The personalized shot changes with every patient - the manufacturing recipe does not.
How the money works
Moderna makes most of its money selling vaccines - to national governments and public-health agencies, to pharmacies and health systems, and increasingly to individuals through the seasonal respiratory market. During the pandemic, revenue spiked into the tens of billions as its COVID vaccine reached hundreds of millions of people. As the emergency faded, so did those numbers: full-year 2025 revenue was roughly $1.9 billion, largely from COVID vaccine sales.
On top of product sales, the company layers collaboration and grant funding that shares both risk and reward. Merck co-develops the cancer program. In March 2024, Blackstone Life Sciences committed up to $750 million to advance the flu program in exchange for milestones and low-single-digit royalties, while Moderna kept full control. The company has also worked with the U.S. government on pandemic preparedness, though a $766 million pandemic-flu contract was cancelled in 2025.
The COVID-era spike and its comedown. The open question is the next chapter - whether flu, RSV and oncology can carry the platform past the pandemic hangover. Figures approximate.
Who else is in the room
Moderna's closest mirror is the Pfizer-BioNTech partnership, and BioNTech itself - the other camp that proved mRNA could work at scale during the pandemic and is now pointing the same technology at cancer. In respiratory disease, Moderna also competes with established vaccine makers such as GSK, Sanofi and Novavax, whose products often rest on older, well-understood technologies. In personalized oncology, the neoantigen field is small but crowded with ambition, with BioNTech among the notable players.
What distinguishes Moderna is less any single product than the way it frames the work. It describes mRNA as an "information molecule" and talks about its business in software terms - a digital-first drug company that leans on automation and a written set of internal "Mindsets." The claim is that a company organized around one reprogrammable platform can move faster than one organized around a shelf of unrelated molecules. The pandemic offered the loudest evidence for that claim; the coming years, in flu and cancer, will test whether it holds when there is no emergency forcing the world to pay attention.
From lab bench to household name
Strip away the pandemic drama and Moderna's story is a plain one about patience. The company picked a hard, general capability, invested through a decade of doubt, and was the only one able to move in weeks when the moment came. Whether the same discipline turns cancer, flu and rare disease into the next act is the question the next few years will answer.